Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
28 hedge funds and large institutions have $1.72M invested in Repros Therapeutics Inc. in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 3 closing their positions.
3% less funds holding
Funds holding: 29 → 28 (-1)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
32% less capital invested
Capital invested by funds: $2.51M → $1.72M (-$791K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$58.2K |
| 2 |
VF
Virtu Financial
New York
|
+$46.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$3.85K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$3.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
-$99K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$44K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.2K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$2K |
| 5 |
AIA
Allegis Investment Advisors
Idaho Falls,
Idaho
|
-$1.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| – | -$35 | -100 | -45% |
|
RPRX Hedge Fund Activity: Q3 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q3 2017, worth a combined $1.72M — down 32% from $2.51M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RPRX and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $58.2K. The largest seller was General American Investors, cutting an estimated $99K.
- 28 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q3 2017, down from 29 in Q2 2017.
- Funds reported $1.72M of Repros Therapeutics Inc. stock for Q3 2017, down 32% quarter-over-quarter.
- 2 funds opened new Repros Therapeutics Inc. positions in Q3 2017 and 3 closed out, a net change of -1 holder.
- The largest Repros Therapeutics Inc. buyer in Q3 2017 was Renaissance Technologies, an estimated $58.2K added.
- The largest Repros Therapeutics Inc. seller in Q3 2017 was General American Investors, an estimated $99K sold.
Based on aggregated 13F filings for Q3 2017.